186 related articles for article (PubMed ID: 36300863)
1. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
[TBL] [Abstract][Full Text] [Related]
2. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
3. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
5. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
[TBL] [Abstract][Full Text] [Related]
6. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
[TBL] [Abstract][Full Text] [Related]
7. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
[TBL] [Abstract][Full Text] [Related]
8. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
10. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
11. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
[TBL] [Abstract][Full Text] [Related]
12. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
13. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
14. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
15. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
17. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
[TBL] [Abstract][Full Text] [Related]
18. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients.
Rosso R; D'Alonzo M; Bounous VE; Actis S; Cipullo I; Salerno E; Biglia N
Curr Oncol; 2023 Jan; 30(2):1461-1472. PubMed ID: 36826073
[TBL] [Abstract][Full Text] [Related]
19. Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.
Labonté M; Guillaumie L; Dionne A; Dorval M; Nabi H; Lemieux J; Provencher L; Lauzier S
Res Social Adm Pharm; 2020 Dec; 16(12):1724-1736. PubMed ID: 32205070
[TBL] [Abstract][Full Text] [Related]
20. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
